Objective: In a sample of 368 postmenopausal women, we (1) determined within-cohort and betweencohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships.
Background
Women with breast cancer comprise the largest group of cancer survivors in the USA, with almost three million women alive today [1] due in part to advances in targeted therapies that prevent recurrence. Aromatase inhibitor (AI) therapy improves disease-free and overall survival for postmenopausal women with hormone-receptor positive breast cancer [2] . This oral anti-estrogen therapy is typically prescribed for at least a 5-year course after mastectomy or breast conserving surgery [2] . Side effects of this therapy reported by some women include perceived changes in cognitive function, such as difficulty with concentration and recall [3] . These cognitive changes may negatively impact meaningful activities such as work, achievement of personal goals, and social interaction [4, 5] , as well as the ability to adhere to prescribed therapy [3] . Previous work by our group demonstrated that perceived cognitive changes negatively impacted long-term AI adherence more than a year after initiation of therapy [3] . Poorer adherence increases risk for recurrence and decreases long-term survival [6] .
AI-associated cognitive changes may be mediated by estrogen deprivation [7, 8] . Estrogen promotes synaptic and neural plasticity in the brain, which contributes to the growth and maintenance of neurons and white matter tracts [9, 10] . Estrogen deprivation may result in brain alterations that manifest as variable phenotypes of objectively measured and self-reported cognitive changes. For women who receive chemotherapy followed by AI therapy, cognitive changes may initiate with chemotherapy [7] and may be potentiated or repaired more slowly because of reduced neural plasticity. Co-occurring symptoms may be associated with poorer cognitive function observed before systemic therapy and may influence cognitive decline over time [11] .
Few studies have examined cognitive function associated with AI therapy in postmenopausal women with breast cancer. Self-report provides valuable information about patients' perceptions of cognitive function, which may differ from results obtained using objective neuropsychological tests [12] . Objective measures were developed to assess cognitive disorders in patients with stroke, neurological trauma, or dementia [13] . Changes in cognitive function and underlying neural circuitry associated with breast cancer and its treatment may be more subtle than what occurs in these disorders. Therefore, inconsistencies between subjective and objective findings could be due to limited ecological validity and a lack of sensitivity of neuropsychological measures to the more subtle changes experienced by women with breast cancer [12] . It is also possible that patients do not notice or are not concerned about cognitive changes identified using neuropsychological measures.
A randomized controlled trial of anastrozole for chemoprevention in healthy women at high risk for breast cancer found no effect on perceived cognitive function during the first 2 years of therapy [14] . Studies of self-reported cognitive function in women with breast cancer found mixed relationships with anti-estrogen therapies (i.e., selective estrogen receptor modulators and AIs). A recent study using the Patient Assessment of Own Functioning Inventory (PAOFI) found that these therapies were associated with poorer language and communication in the first 6 months of therapy [15] . A cross-sectional study conducted a mean of 3 years after the initiation of therapy using the Functional Assessment of Cancer Therapy Cognitive Scale, and the Cognitive Symptom Checklist found associations among anti-estrogen therapies, poorer cognitive function, and worse mood [16] . A longitudinal study in which patients were assessed using the Cognitive Failures Questionnaire before and after cessation of anti-estrogen therapy found no change in self-reported cognitive function 1 year after completion of therapy [17] , although neuropsychological performance improved during this period [18] . Because these studies included both premenopausal and postmenopausal women, it was not possible to determine the specific effect of AI therapy. No studies have evaluated self-reported cognitive functioning exclusively in postmenopausal women scheduled to receive anastrozole from before the initiation of adjuvant systemic therapy (i.e., a true pre-therapy assessment) through the first 18 months of therapy.
Therefore, the purposes of this study, in a multiplecohort sample of 368 postmenopausal women, were to (1) determine within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluate the influence of co-occurring symptoms, neuropsychological function, and other covariates on these relationships.
Methods

Participants and settings
This analysis is part of a longitudinal study of cognitive function in postmenopausal women receiving the AI, anastrozole, for invasive breast cancer (CA107408) [19] . The University of Pittsburgh Institutional Review Board approved the study. Eligible women were postmenopausal and ≤75 years of age, were able to speak and read English, had completed a minimum of 8 years of education, had no history of neurological illness or previous cancer (except non-melanoma skin cancer), were not receiving hormone replacement therapy, and had no hospitalizations for psychiatric illness within 2 years. Women with breast cancer were recruited 2005-2012 from the Magee-Women's Breast Cancer Program of the University of Pittsburgh Cancer Institute. These women were newly diagnosed with stage I-IIIA breast cancer, had completed surgery, and were scheduled to receive anastrozole alone (n = 158) or chemotherapy followed by anastrozole (n = 104). We recruited a sample of postmenopausal controls without breast cancer (n = 106), which was matched as closely as possible for age and education using frequency matching within a range of ±3 years of age. Controls were recruited during the same time period as patients through the University Center for Social and Urban Research via random digit dialing, response to an advertisement, or referral by patients in the study.
Instruments
Demographic and clinical characteristics were collected at enrollment, and clinical characteristics were verified using the medical record. The PAOFI was used to assess selfreported global cognitive function (i.e., total score) as well as higher-level cognitive and intellectual functions, memory, language and communication, and use of hands/ sensory-perceptual function (i.e., sensorimotor function) using four subscales [20] . For each of the 32 items, frequency of cognitive problems was rated on a 6-point scale ranging from 0 (almost never) to 5 (almost always). Higher summed scores indicate poorer perceived functioning (range 0-160). The PAOFI was previously used in studies of women with breast cancer [12, 15, 21] . It has acceptable construct [20] and discriminant [22] validity. The PAOFI is unique among self-report cognitive measures in that it assesses sensorimotor function, which may be affected by neuropathies associated with chemotherapies (e.g., taxanes). Findings from factor analysis [20] support the combination of the original use of hands and sensory-perceptual subscales into one sensorimotor subscale. In the current study, internal consistency of the PAOFI as determined using Cronbach's alpha was 0.92 for the total score, 0.88 for higher-level cognitive and intellectual functions, 0.82 for memory, 0.80 for language and communication, and 0.61 for sensorimotor function.
Potential covariates of self-reported cognitive function included age and well-validated measures of estimated verbal intelligence (National Adult Reading Test-Revised [23] [27] ). The presence of neuropathic symptoms was evaluated by endorsement of the 'numbness or tingling' item of the BCPT. As reported previously [19] , neuropsychological function was assessed with a battery of measures evaluating multiple cognitive domains. See Supporting Information Table S1 for a summary of the measures, outcome variables, and ranges of scores that comprised these domains.
Study procedures
Of the eligible women approached, 397 (49% response rate) provided written informed consent. All patients completed baseline assessments before initiating AI therapy. Patients receiving chemotherapy completed a baseline assessment before the first cycle and completed a pre-AI assessment after the last cycle. Patients were assessed every 6 months thereafter, for a total of four assessments over 18 months. The distribution of every 6-month assessments was chosen to maximize the number of assessments while minimizing practice effects for neuropsychological tests. Controls were assessed at matched time points. Participants who completed at least the baseline assessment for self-reported cognitive and symptom measures (n = 368) were included in this analysis.
Statistical methods
Descriptive statistics and frequency distributions were generated using SPSS Statistics 22 (IBM, New York) to characterize the three cohorts of participants and to identify data anomalies. Analysis of variance and the chisquare test were used to evaluate for differences among the cohorts at enrollment. Fisher's exact test was used if unexpected cell counts existed. If data transformations did not correct for non-parametric distributions, the Kruskal-Wallis or Mann-Whitney U-test was used. Baseline differences among the cohorts were considered statistically significant at p < 0.05. For post hoc pairwise contrasts using the Bonferroni correction, p < 0.017 (i.e., 0.05/3) was considered significant.
Because PAOFI sum scores were non-parametric, total and subscale scores were square-root transformed for longitudinal modeling. Multilevel regressions using STATA SE 13 (StataCorp, Texas) employed a backward stepwise approach to identify a parsimonious set of covariates from demographic, clinical, and symptom characteristics that significantly differed among the groups at baseline. Controlling for age and estimated verbal intelligence, significant covariates retained for final modeling included baseline levels of anxiety, depressive symptoms, and fatigue. Because performance in the domains of executive function, visual working memory, and concentration previously was found to vary significantly among the three cohorts [19] , we evaluated for associations between PAOFI scores and these neuropsychological domains using a multi-level random intercepts model in which change over time was nested within individuals, which were nested within the cohorts.
Mixed-effects modeling using SAS 9.4 (SAS Institute, North Carolina) was carried out to determine relationships between AI therapy and PAOFI scores within cohorts and between cohorts over time. Modeling proceeded in three steps: (1) an unadjusted model for the PAOFI total score was generated to determine how scores changed over time, (2) baseline differences in age and estimated verbal intelligence were controlled, and (3) covariate-adjusted final models were generated. Mean sum scores and standard errors reported in the figures were back-transformed from model-generated values. Where significant (i.e., p < 0.05) overall cohort-by-time effects were found in the final models, within-cohort and between-cohort differences were evaluated using a more conservative alpha of 0.01 to reduce the risk of type I error. Effect sizes were calculated using standardized mean difference (i.e., d).
Results
Differences among the cohorts
At enrollment, women scheduled to receive anastrozole alone were older (p's < 0.01), while controls without breast cancer had higher estimated verbal intelligence (p's ≤ 0.001), than other participants (Table 1) . A greater proportion of women scheduled to receive chemotherapy followed by anastrozole had mastectomies and higher stage of disease. These patients reported greater average pain than controls (p = 0.002) and greater anxiety than other participants (p's ≤ 0.001; Table 2 ). No differences were found between the patient cohorts in receipt of radiation therapy, weeks since diagnosis, or weeks since first surgery; and no differences were found among the three cohorts in other demographic or symptom characteristics. Participants who did not complete all time points of the study (n = 177) reported poorer language and communication subscale scores (U = 14,457.0; p = 0.016) and greater total symptom burden (t = 2.3, p = 0.024) at enrollment than participants who completed the entire study (n = 191). Although no differences in completion were found between the patient cohorts or between the women who received chemotherapy followed by anastrozole and controls, a smaller proportion of women who took anastrozole alone (46.2%) completed the entire study compared with controls (64.2%; p = 0.006). See Supporting Information Figure S1 for CONSORT diagram.
Longitudinal findings Figure 1 shows model-predicted, unadjusted trajectories for PAOFI total scores for the three cohorts. Controlling for age, estimated verbal intelligence, and symptom covariates (i.e., baseline BDI-II, POMS tension/anxiety, and POMS fatigue/inertia scores), an overall cohort-by-time effect was found (p < 0.001). Women reported deterioration in global cognitive function from before the initiation of chemotherapy to after the last cycle of chemotherapy (p < 0.001, d = 0.23), which persisted after 1 year of anastrozole (p < 0.001, d = 0.29). Although controls reported poorer cognitive function than both patient cohorts at enrollment (p < 0.01, d = 0.15), no within-cohort or between-cohort differences were found after the initiation of anastrozole. Controls reported no change over time in global cognitive function. Figure 2 shows unadjusted cohort trajectories for PAOFI subscale scores. Controlling for covariates, overall cohort-by-time effects were found for all subscales (p's < 0.05). At enrollment, controls reported poorer memory than patients who would receive anastrozole alone (p = 0.008, d = 0.14), and poorer sensorimotor Before the initiation of anastrozole, patients who received chemotherapy reported poorer memory than the women who would receive anastrozole alone (p = 0.006, d = 0.13). The poorer higher-level cognitive and intellectual functions subscale scores observed after chemotherapy were not significant, but these poorer scores became significant by 12 months after the initiation of AI therapy (p < 0.001, d = 0.23). No within-cohort or between-cohort differences in subscale scores were found during any 6-month period after the initiation of anastrozole. Controls reported no significant change over time in subscale scores. Neuropsychological performance in three cognitive domains (i.e., executive function, visual working memory, and concentration) previously was reported to differ significantly among the cohorts [19] . When controlling for PAOFI total score at baseline, time-varying total score was a significant predictor of executive function z-scores (p = 0.048). This longitudinal association held for the higher-level cognitive and intellectual functions subscale score (p = 0.015). PAOFI total score at baseline was a significant predictor of visual working memory z-scores (p = 0.005), although the time-varying total score was not significant when controlling for baseline scores. This baseline association held for the higher-level cognitive and intellectual functions (p = 0.003), language and communication (p = 0.001), and sensorimotor (p = 0.011) subscale scores. For all these associations, as PAOFI scores increased, indicating poorer self-reported cognitive function, z-scores decreased, indicating worse performance in these cognitive domains. The relationships did not change when controlling for symptom covariates. PAOFI scores were not related to concentration z-scores.
Conclusions
These findings provide further evidence of poorer selfreported cognitive function after chemotherapy but do not support perceived cognitive changes in the first 18 months of AI therapy alone. Because poor mood and fatigue are common predictors of poor self-reported cognitive function, these symptoms could account for associations between treatment and perceived cognitive function. However, controlling for age, estimated verbal intelligence, and these co-occurring symptoms did not remove the significant impact of chemotherapy on cognitive function, which persisted throughout the study. The effect sizes for these cognitive changes were small and may not have been clinically meaningful (i.e., d < .5), because mean sum scores corresponded to an average report of experiencing cognitive problems very infrequently. While on average, women in the study did not report clinically meaningful cognitive changes, future studies should evaluate for subgroups of women at increased risk.
Clinically, the patient groups differed because treatment is based on disease characteristics. However, disease and treatment characteristics were not associated with cognitive changes in this study, which is consistent with findings from previous reports [28] . It is interesting that patients did not report worse cognitive function over time compared with postmenopausal controls. We explored whether differences in comorbidities experienced by the controls at baseline could explain this finding. The most common comorbidities for all participants were hypertension (42.1%, n = 155), osteoarthritis (34.2%, n = 126), and hyperlipidemia (27.4%, n = 101). The frequency of type 1 (n = 6) and type 2 (n = 37) diabetes was 11.7%. Of these comorbidities, the cohorts differed only in the frequency of osteoarthritis, with a significantly lower proportion of the control group (22.6%, n = 24) experiencing it than patients receiving chemotherapy followed by anastrozole (42.3%, n = 44; FE p = 0.002). Although this difference does not explain our finding, comorbidities may play an important role in perceived cognitive function. It is also possible that stress associated with either a diagnosis of cancer or comorbid conditions influences self-reported cognitive function during cancer therapy [29] . Poorer perceived cognitive function over time was associated with greater baseline levels of depressive symptoms, anxiety, and fatigue. However, most participants (89.9%, n = 331) reported minimal depressive symptoms at baseline. Only 3.8% of participants (n = 14) reported moderate to severe levels of depressive symptoms, which did not vary significantly among the cohorts. Moreover, participants on average reported significantly lower anxiety (p < .001) and fatigue (p < .001) than an adult female normative sample [26] , which may in part be due to the fact that the normative sample included younger adults aged 18-65 years. Jenkins et al. [14] found that worse mood, but not receipt of anastrozole, was associated with poorer perceived cognitive function during chemoprevention in women at high risk for breast cancer. Biglia et al. [30] found that worse mood during chemotherapy was associated with poorer perceived cognitive function before anti-estrogen therapy in a mixed sample of premenopausal and postmenopausal women with breast cancer. Breckenridge et al. [16] found that, while mood was not associated with anti-estrogen therapy, worse mood was associated with poorer perceived cognitive function in women a mean of 3 years post-primary therapy for breast cancer. Clinicians should evaluate women for poor mood before systemic therapy, because addressing these symptoms early may improve perceived cognitive function. Adherence to therapy may also improve [3] . However, poor mood does not explain all self-reported cognitive changes during cancer therapy [31] , which suggests that interventions should be chosen depending on whether mood disturbance is present [32] .
A recent study found that, while perceived cognitive function did not change during the first 6 months of AI therapy, cerebral metabolic activity did change compared with controls [33] . This finding suggests that AI therapy alters brain function but that this alteration is not noticeable by patients early in AI therapy. Although we similarly found no differences in self-reported cognitive function either within or between cohorts after initiation of anastrozole, we previously reported that differences were found during this time in three domains of neuropsychological function (i.e., executive function, visual working memory, and concentration) [19] . The associations we found between self-reported cognitive function and the domains of executive function and visual working memory were significant, but the percent residual variance in domain z-scores explained by PAOFI scores was very small (i.e., <1%). It is possible that these neuropsychological changes were too subtle to be perceived or that women were not concerned about these changes in the first 18 months of therapy. However, Ganz et al. [12] found that poorer memory subscale scores on the PAOFI were associated with worse verbal memory performance, and that, similar to our findings, poorer higher-level cognitive and intellectual functions subscale scores were associated with worse visual memory performance approximately 7 months after breast cancer diagnosis compared with controls. In a cross-sectional study of women an average of 19 months after initiation of selective estrogen receptor modulators or AI therapy, Bender et al. [31] found that poorer PAOFI scores were associated with worse performance on individual neuropsychological tests of verbal learning and memory. Neuropsychological changes may become more noticeable with longer duration of AI therapy, and longitudinal neuroimaging assessments may help determine if AI therapy impacts underlying neural circuitry over time.
Receipt of taxanes by 70% of the women who received chemotherapy may have influenced our findings of poorer sensorimotor function and poorer PAOFI total scores after chemotherapy. Indeed, a greater proportion of women who received chemotherapy reported neuropathic symptoms (i.e., tingling and numbness; 50.6%; p < 0.001) before beginning AI therapy compared with women who would receive anastrozole alone (25.9%) or controls (25.5%). Because the PAOFI is unique in its incorporation of sensorimotor function into its total score, our finding of perceived changes in cognitive function after chemotherapy might be explained in part by the occurrence of neuropathy in this cohort. However, significant worsening was found from before to after chemotherapy for memory, language and communication, and sensorimotor functioning. Therefore, it is unlikely that the sensorimotor subscale score alone is driving the finding of poorer overall cognitive function after chemotherapy for the total score.
Unlike a common finding in other studies, age was not a significant predictor of self-reported cognitive function. Younger patients generally report greater severity for symptoms than older patients [34] . Therefore, the lack of a relationship between age and perceived cognitive function may be due to the inclusion of only postmenopausal women in our sample. The Critical Window Theory suggests that estrogen replacement is the most protective of cognitive function during the peri-menopausal period [35] . Therefore, estrogen deprivation in the postmenopausal period after this critical window may not have a noticeable effect on cognitive function [36] . Accelerated aging may explain the effect of adjuvant therapies on cognitive function [7, 37] . In a recent cross-sectional study conducted after mixed adjuvant therapies, poorer PAOFI language and communication scores were associated with electroencephalograph slowing, similar to what is found in aging [38] . Because postmenopausal women in our sample may already have experienced some aging effects, aging effects attributable to adjuvant systemic therapy may have been less noticeable to them.
Limitations
This study was limited by a sample of mostly White and well-educated women. Although we controlled for baseline differences in participant characteristics that remained in final models, differences among the cohorts may have influenced our findings. All patients received general anesthesia for breast cancer surgery prior to enrollment, which may have influenced their cognitive functioning. While we found no differences in the receipt of radiation therapy among the patient cohorts, radiation therapy has been associated with multiple symptoms [39] , including long-term changes in cognitive function [40] . Although cognitive changes occurred primarily during the period of chemotherapy, without comparison with a cohort receiving chemotherapy alone, it is not possible to evaluate additive effects of AI therapy after chemotherapy versus long-term effects of chemotherapy.
We did not evaluate the effect of specific comorbidities on trajectories of cognitive function. Attrition was greatest in the cohort that received AI therapy alone, which was due in part to the fact that 57.8% (n = 48) of patients who dropped out were switched from anastrozole to other AI therapies, which excluded them from further participation in the study. Because these patients stopped taking anastrozole due to side effects, the women who continued in the study may have noticed less impact on cognitive function.
Implications
In summary, we found that chemotherapy followed by anastrozole, but not AI therapy alone, was associated with poorer self-reported cognitive function during adjuvant systemic therapy. The effects of other treatments, such as surgery and radiation therapy, may impact these relationships, although in this sample no differences were found in self-reported cognitive function compared with postmenopausal controls without breast cancer. Regardless of cohort membership, poorer self-reported cognitive function was associated with poorer mood and fatigue, as well as worse neuropsychological performance, which suggests that baseline characteristics of participants at higher risk may predict cognitive changes more so than treatment. Although women in our study did not report clinically meaningful cognitive changes on average, future studies should evaluate for subgroups of participants at higher risk for cognitive changes over the full course of AI therapy.
